Is CSL part of the ASX 100 index?

Yes, CSL Ltd is a constituent of the ASX 100 index, representing some of the largest companies on the Australian Securities Exchange.

What type of products does Pro Medicus develop?

Pro Medicus develops radiology IT solutions, including RIS, PACS, and advanced visualisation tools, used by healthcare providers globally.

Do CSL and PME operate in the same segment of healthcare?

Not exactly. CSL focuses on biotechnology and treatments for serious health conditions, while PME specialises in radiology and medical imaging technology.

Exploring (ASX:CSL) and (ASX:PME): Two ASX 100 Stocks Worth a Closer Look

3 min read | August 05, 2025 08:27 PM AEST | By Team Kalkine Media

Google News:

Exploring (ASX:CSL) and (ASX:PME): Two ASX 100 Stocks Worth a Closer Look — Image source: Shutterstock

CSL Ltd – A Pillar in Global Biotechnology

CSL Ltd (ASX:CSL), part of the ASX 100 stocks, stands as one of Australia’s most recognised healthcare companies. Originally established as a government entity, CSL has evolved into a global biotechnology powerhouse. Its operations span three major segments: CSL Behring, CSL Seqirus, and CSL Vifor.

CSL Behring specialises in blood plasma therapies, delivering treatments for serious and rare medical conditions. CSL Seqirus focuses on influenza prevention and pandemic response solutions, while CSL Vifor addresses iron deficiency and kidney-related health challenges. Over the decades, CSL has built a reputation for consistency, stability, and innovation in the healthcare space.

While market conditions may shift, CSL’s history of delivering strong results and its established place in the healthcare sector keep it in the spotlight for investors seeking exposure to large-scale, global medical companies.

Pro Medicus Ltd – Transforming Medical Imaging

Innovative Solutions for Healthcare Providers

Pro Medicus Ltd (ASX:PME) has made its mark as a provider of advanced radiology IT systems, serving hospitals, imaging centres, and healthcare groups worldwide. The company offers a comprehensive suite of solutions, including Radiology Information Systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualisation tools.

Driving Efficiency in Medical Imaging

These systems streamline critical processes such as patient scheduling, imaging interpretation, and report generation. The technology enables faster, more accurate diagnostic decisions, benefiting both healthcare professionals and patients. As medical imaging plays an increasingly central role in healthcare delivery, PME’s capabilities position it as a key contributor to the industry’s technological advancement.

CSL and PME operate in distinct but complementary areas of the healthcare sector. CSL’s scale and global reach are balanced by PME’s focus on innovation and efficiency in medical imaging. Both companies exemplify the strength and diversity within Australia’s healthcare-related listed businesses, and their ongoing developments will be closely followed by market watchers.

Frequently Asked Questions

Is CSL part of the ASX 100 index?
Yes, CSL Ltd is a constituent of the ASX 100 index, representing some of the largest companies on the Australian Securities Exchange.
What type of products does Pro Medicus develop?
Pro Medicus develops radiology IT solutions, including RIS, PACS, and advanced visualisation tools, used by healthcare providers globally.
Do CSL and PME operate in the same segment of healthcare?
Not exactly. CSL focuses on biotechnology and treatments for serious health conditions, while PME specialises in radiology and medical imaging technology.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.